Check J H, Sarumi M, DiAntonio A, Hunter K, Simpkins G, Duroseau M
Clin Exp Obstet Gynecol. 2015;42(5):563-7.
To determine if an immunomodulatory protein (progesterone induced blocking factor [PIBF]) that is progesterone induced and found in higher concentration during pregnancy is similarly found with increased levels in women with gynecologic cancers.
A newly developed enzyme linked immunoabsorbent assay (ELISA) assay was used to measure PIBF in the sera of six women with various gynecologic cancers and compare them to five controls (three with benign tumors and two having gynecologic procedures for non-tumors.
The PIBF levels in women with gynecologic cancer did not rise precipitously as historical controls of women or men exposed to progesterone. The two highest PIBF levels of the 11 subjects were in women with gynecologic cancer.
The data suggest that if PIBF helps cancer cells to evade immune surveillance, it probably operates through an intracytoplasmic presence. If an increase in sera PIBF could have been detected in women with gynecologic cancer, then this ELISA test could have been used to detect tumor recurrence. Future studies may concentrate on evaluating intracytoplasmic PIBF to possibly help determine which tumors may respond to progesterone antagonist receptors.
确定一种免疫调节蛋白（孕酮诱导阻断因子[PIBF]），它由孕酮诱导产生，在孕期浓度更高，探究其在妇科癌症患者体内水平是否也会升高。
采用新开发的酶联免疫吸附测定（ELISA）法检测6例患有不同妇科癌症的女性血清中的PIBF，并将其与5例对照（3例患有良性肿瘤，2例因非肿瘤性疾病接受妇科手术）进行比较。
与接触过孕酮的女性或男性的历史对照相比，妇科癌症患者的PIBF水平并未急剧上升。11名受试者中PIBF水平最高的两人为妇科癌症患者。
数据表明，如果PIBF有助于癌细胞逃避免疫监视，它可能通过在细胞质内存在发挥作用。如果能在妇科癌症患者中检测出血清PIBF升高，那么这种ELISA检测可用于检测肿瘤复发。未来研究可能集中于评估细胞质内PIBF，以帮助确定哪些肿瘤可能对孕酮拮抗剂受体有反应。
